|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Z, Ouyang L, Peng H and Zhang WZ:
Oridonin: Targeting programmed cell death pathways as an
anti-tumour agent. Cell Prolif. 45:499–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu DL, Bu HQ, Jin HM, Zhao JF, Li Y and
Huang H: Enhancement of the effects of gemcitabine against
pancreatic cancer by oridonin via the mitochondrial
caspase-dependent signaling pathway. Mol Med Rep. 10:3027–3034.
2014.PubMed/NCBI
|
|
5
|
Bu HQ, Luo J, Chen H, Zhang JH, Li HH, Guo
HC, Wang ZH and Lin SZ: Oridonin enhances antitumor activity of
gemcitabine in pancreatic cancer through MAPK-p38 signaling
pathway. Int J Oncol. 41:949–958. 2012.PubMed/NCBI
|
|
6
|
Liu J, Huang R, Lin D, Wu X, Peng J, Lin
Q, Pan X, Zhang M, Hou M and Chen F: Apoptotic effect of oridonin
on NB4 cells and its mechanism. Leuk Lymphoma. 46:593–597. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Y, Liu JH, Chai K, Tashiro S, Onodera
S and Ikejima T: Inhibition of c-Met promoted apoptosis, autophagy
and loss of the mitochondrial transmembrane potential in
oridonin-induced A549 lung cancer cells. J Pharm Pharmacol.
65:1622–1642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM,
Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via
PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta
Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang CL, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Oridonin induced A375-S2 cell apoptosis via
bax-regulated caspase pathway activation, dependent on the
cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res. 6:127–138.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao SY, Li J, Qu XY, Zhu N and Ji YB:
Downregulation of Cdk1 and cyclinB1 expression contributes to
oridonin-induced cell cycle arrest at G2/M phase and growth
inhibition in SGC-7901 gastric cancer cells. Asian Pac J Cancer
Prev. 15:6437–6441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boohaker RJ and Xu B: The versatile
functions of ATM kinase. Biomed J. 37:3–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan HQ, Huang XB, Ke SZ, Jiang YN, Zhang
YH, Wang YN, Li J and Gao FG: Interleukin 6 augments lung cancer
chemotherapeutic resistance via ataxia-telangiectasia
mutated/NF-kappaB pathway activation. Cancer Sci. 105:1220–1227.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsia SM, Yu CC, Shih YH, Chen M Yuanchien,
Wang TH, Huang YT and Shieh TM: Isoliquiritigenin as a cause of DNA
damage and inhibitor of ataxia-telangiectasia mutated expression
leading to G2/M phase arrest and apoptosis in oral squamous cell
carcinoma. Head Neck. 38:(Suppl 1). E360–E371. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Zhang X, Teng L and Legerski RJ:
DNA damage checkpoint recovery and cancer development. Exp Cell
Res. 334:350–358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stark GR and Taylor WR: Control of the
G2/M transition. Mol Biotechnol. 32:227–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oak CH, Wilson D, Lee HJ, Lim HJ and Park
EK: Potential molecular approaches for the early diagnosis of lung
cancer (review). Mol Med Rep. 6:931–936. 2012.PubMed/NCBI
|
|
17
|
Tian W and Chen SY: Recent advances in the
molecular basis of anti-neoplastic mechanisms of oridonin. Chin J
Integr Med. 19:315–320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li D, Xu S, Cai H, Pei L, Zhang H, Wang L,
Yao H, Wu X, Jiang J, Sun Y and Xu J: Enmein-type diterpenoid
analogs from natural kaurene-type oridonin: Synthesis and their
antitumor biological evaluation. Eur J Med Chem. 64:215–221. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ikezoe T, Chen SS, Tong XJ, Heber D,
Taguchi H and Koeffler HP: Oridonin induces growth inhibition and
apoptosis of a variety of human cancer cells. Int J Oncol.
23:1187–1193. 2003.PubMed/NCBI
|
|
20
|
Chen G, Wang K, Yang BY, Tang B, Chen JX
and Hua ZC: Synergistic antitumor activity of oridonin and arsenic
trioxide on hepatocellular carcinoma cells. Int J Oncol.
40:139–147. 2012.PubMed/NCBI
|
|
21
|
Liu Y, Liu YZ, Zhang RX, Wang X, Meng ZJ,
Huang J, Wu K, Luo JY, Zuo GW, Chen L, et al: Oridonin inhibits the
proliferation of human osteosarcoma cells by suppressing
Wnt/β-catenin signaling. Int J Oncol. 45:795–803. 2014.PubMed/NCBI
|
|
22
|
Gao FH, Liu F, Wei W, Liu LB, Xu MH, Guo
ZY, Li W, Jiang B and Wu YL: Oridonin induces apoptosis and
senescence by increasing hydrogen peroxide and glutathione
depletion in colorectal cancer cells. Int J Mol Med. 29:649–655.
2012.PubMed/NCBI
|
|
23
|
Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li
Y and Cui JH: Oridonin induces apoptosis in SW1990 pancreatic
cancer cells via p53- and caspase-dependent induction of p38 MAPK.
Oncol Rep. 31:975–982. 2014.PubMed/NCBI
|
|
24
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kikuchi K, Hettmer S, Aslam MI, Michalek
JE, Laub W, Wilky BA, Loeb DM, Rubin BP, Wagers AJ and Keller C:
Cell-cycle dependent expression of a translocation-mediated fusion
oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS
Genet. 10:e10041072014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schafer KA: The cell cycle: A review. Vet
Pathol. 35:461–478. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Falck J, Coates J and Jackson SP:
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of
DNA damage. Nature. 434:605–611. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jazayeri A, Falck J, Lukas C, Bartek J,
Smith GC, Lukas J and Jackson SP: ATM- and cell cycle-dependent
regulation of ATR in response to DNA double-strand breaks. Nat Cell
Biol. 8:37–45. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee JH and Paull TT: ATM activation by DNA
double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science.
308:551–554. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oren M and Rotter V: Introduction: p53-the
first twenty years. Cell Mol Life Sci. 55:9–11. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meek DW: Regulation of the p53 response
and its relationship to cancer. Biochem J. 469:325–346. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang X, Simpson ER and Brown KA: p53:
Protection against tumor growth beyond effects on cell cycle and
apoptosis. Cancer Res. 75:5001–5007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Douglas P, Zhong J, Ye R, Moorhead GB, Xu
X and Lees-Miller SP: Protein phosphatase 6 interacts with the
DNA-dependent protein kinase catalytic subunit and dephosphorylates
gamma-H2AX. Mol Cell Biol. 30:1368–1381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kinner A, Wu W, Staudt C and Iliakis G:
Gamma-H2AX in recognition and signaling of DNA double-strand breaks
in the context of chromatin. Nucleic Acids Res. 36:5678–5694. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bakkenist CJ and Kastan MB: DNA damage
activates ATM through intermolecular autophosphorylation and dimer
dissociation. Nature. 421:499–506. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reinhardt HC and Yaffe MB: Kinases that
control the cell cycle in response to DNA damage: Chk1, Chk2 and
MK2. Curr Opin Cell Biol. 21:245–255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gerić M, Gajski G and Garaj-Vrhovac V:
γ-H2AX as a biomarker for DNA double-strand breaks in
ecotoxicology. Ecotoxicol Environ Saf. 105:13–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
